Carbamazepine: A bioequivalence study and limited sampling modeling

International Journal of Clinical Pharmacology and Therapeutics

Volumn 40, Issue 9, 2002, Pages 424-430

  Suarez Kurtz, G ^a   Ribeiro, F M ^a   Salvadori, M C ^a   Struchiner, C J ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Bioequivalence; Carbamazepine; Limited sampling models

Indexed keywords

CARBAMAZEPINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; SAMPLING; STATISTICAL MODEL; VOLUNTEER;

EID: 0036729790     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP40424     Document Type: Article

References (14)

1. Regressions by leaps and bounds
2. A comparison of methods for LSS design using data from a phase I trial of the anthapyrazole DuP-941
3. A limited sampling approach in bioequivalence studies
4. max of carbamazepine and carbarnazepine epoxide following a single and multiple dose of a sustained-release product
5. A limited sampling model for vinblastine pharmacokinetics
6. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability
7. Limited sampling strategies for itraconazole and hydroxy-itraconazole based on data from a bioequivalence study
8. Limited sampling strategies for studying the pharmacokinetics of amlodipine
9. Limited sampling strategy models for estimating the pharmacokinetic parameters of 4-methylaminoantipyrine, an active metabolite of dipyrone
10. Development and validation of limited sampling strategies for predicting amoxicillin pharmacokinetic and pharmacodynamic parameters
11. Limited sampling approach